‘Pipeline In A Product’ Nipocalimab Starts Delivering For J&J
Moving Into Phase III For HDFN
Executive Summary
Johnson & Johnson splashed a lot of cash to get hold of the FcRn inhibitor and is exploring nearly a dozen indications. Nipocalimab has advanced in one of those this week, severe hemolytic disease of the fetus and newborn.
You may also be interested in...
J&J Gets Two Studies Closer To $5bn Sales Goal For Nipocalimab
Analysts said full data from the VIVACITY study in generalized myasthenia gravis would be key to determining the drug’s competitive profile against approved anti-FcRn agents.
J&J In Immunology: 'We Plan To Lead The Orals Market'
Johnson & Johnson’s historical strength in immunology will form the foundation of a renewed push in the field, with novel candidates for indications such as psoriasis, arthritis and inflammatory bowel disease.
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.